Detailed narrative
New CEO Priorities and Strategic Focus
Mike McCormick, the newly appointed President and CEO, outlined three core objectives: increasing Aquadex utilization and recurrent circuit revenue, expanding presence in pediatrics and adult critical care, and strategically broadening the cardiorenal platform. He emphasized leveraging existing strengths like the growing installed base and strong institutional relationships to build a scalable and financially disciplined business.
Aquadex Platform Expansion and Utilization
The company is focused on driving sustained clinical use of Aquadex by concentrating on accounts and clinical pathways, measuring progress by consistent utilization, patients treated, and recurring circuit revenue. Software updates are being implemented to improve workflow efficiency and treatment precision, alongside developing higher flow capabilities and an enhanced SmartView user interface for critical care.
Pediatric Growth Strategy
Nuwellis is strengthening its pediatric presence through commercial expansion into new states (Michigan, Wisconsin), supporting educational foundations like PC4, and pursuing a regulatory pathway to expand the Aquadex indication from 20kg to 5kg and above. A pre-submission meeting with the FDA provided clarity, with a submission planned for Q4 2026.
Critical Care Opportunity and Physician Training
Adult critical care represents another significant growth area, with initiatives to expand Aquadex capabilities for more complex environments. A recent Critical Care Cardiac Education Summit trained over 280 physicians, creating one of the largest concentrated training initiatives in the company's history, aiming to connect clinical awareness with focused account development.
Cardiorenal Platform Broadening with Clarity Prime
The acquisition of Rendiatech in Q1 2026 added Clarity Prime, an automated kidney function monitoring system, to the development portfolio. Clarity Prime is expected to launch in 2027 and will complement Aquadex by providing earlier and more continuous insights into kidney function, supporting better-informed decisions in cardiorenal care.
Intellectual Property and Capital Discipline
Nuwellis received a notice of allowance for its dual lumen midline catheter technology, strengthening its fluid management platform. The company maintains capital discipline, concentrating resources on Aquadex utilization, pediatric label expansion, Clarity Prime development, and strategic opportunities that directly support its core strategy.